Since loss-of-function mutations of the PCSK9 gene were found to be associated with a 28% reduction in LDL-C levels and an 88% reduction in the risk of coronary heart disease (CHD) in black individuals and with a 15% reduction in LDL-C and a 47% risk reduction in whites [3], an intense effort to develop the optimal method for blocking the action of PCSK9, especially from the part of the pharmaceutical industry, was initiated. The gene discussed is PCSK9; the disease is coronary artery disorder.